Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M, Koca S, Uğurlu MÜ, Ekren R, Peker Eyüboğlu İ, Alan Ö, Erzik C, Güllü Amuran G, Telli TA, Güllüoğlu MB, Sezerman U, Yumuk PF. Akkiprik M, et al. Among authors: yumuk pf. Clin Breast Cancer. 2020 Aug;20(4):332-343.e3. doi: 10.1016/j.clbc.2020.02.006. Epub 2020 Feb 26. Clin Breast Cancer. 2020. PMID: 32201164
Another adverse effect of vemurafenib: Gingival hyperplasia.
Salman A, Tekin B, Koca S, Akgul Babacan N, Yumuk PF, Ergun T. Salman A, et al. Among authors: yumuk pf. J Dermatol. 2016 Jun;43(6):706-7. doi: 10.1111/1346-8138.13248. Epub 2015 Dec 24. J Dermatol. 2016. PMID: 26703083 No abstract available.
Chordoma: a case series and review of the literature.
Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Alan O, et al. Among authors: yumuk pf. J Med Case Rep. 2018 Aug 27;12(1):239. doi: 10.1186/s13256-018-1784-y. J Med Case Rep. 2018. PMID: 30145982 Free PMC article. Review.
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O, Kuzhan O, Koca S, Telli TA, Basoglu T, Ercelep O, Filinte D, Sengul Y, Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF. Alan O, et al. Among authors: yumuk pf. J Oncol Pharm Pract. 2020 Jun;26(4):1011-1018. doi: 10.1177/1078155219879757. Epub 2019 Oct 15. J Oncol Pharm Pract. 2020. PMID: 31615346 Review.
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC, Alan Ö, Başoğlu Tüylü T, Akın Telli T, Arıkan R, Çiçek FC, Ercelep Ö, Öztürk MA, Alsan Çetin İ, Ergelen R, Tinay İ, Akgül Babacan N, Kaya S, Dane F, Yumuk PF. Demircan NC, et al. Among authors: yumuk pf. J Oncol Pharm Pract. 2020 Jul;26(5):1147-1155. doi: 10.1177/1078155219890032. Epub 2019 Dec 2. J Oncol Pharm Pract. 2020. PMID: 31793376
Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF. Demirelli B, et al. Among authors: yumuk pf. Nutr Cancer. 2021;73(2):230-238. doi: 10.1080/01635581.2020.1749290. Epub 2020 Apr 9. Nutr Cancer. 2021. PMID: 32270713
92 results